Media and Press Releases

April 23, 2025 / Brochure

Pioneer Antibody Discovery Platform

The Pioneer Antibody Discovery Platform is a new state-of-the-art therapeutic antibody generation service. With decades of phage display and antibody engineering experience, Bio-Rad™ provides cutting-edge tools for lead generation discovery and optimization to bring you the best-in-class biologic candidates. By tailoring our services to your specific needs, our team of specialists accelerates and simplifies your journey to identify functional biologics for your target of interest..

July 31, 2024 / Press Release

Bio-Rad's Study Demonstrating Utility of its SpyLock Technology for Fast Generation and Screening of Bispecific Antibodies Published in Nature Communications

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the publication of a peer-reviewed study in Nature Communications, "Engineered Reversible Inhibition of SpyCatcher Reactivity Enables Rapid Generation of Bispecific Antibodies"¹. The study demonstrates the utility of Bio-Rad’s SpyLock technology for the rapid generation and screening of bispecific antibodies, allowing greatly accelerated functional validation of bispecifics and identification of the most promising candidates.

July 29, 2024 / Press Release

Bio-Rad Adds Rapid Bispecific Antibody Prototyping and Screening Services to Pioneer Antibody Discovery Platform

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the expansion of its Pioneer Antibody Discovery Platform services with the addition of fast generation and screening of bispecific antibodies, based on the company’s proprietary SpyLock Technology.

June 26, 2024 / Webinar

The Pioneer Antibody Discovery Platform: From Difficult Targets to Modular Antibodies and Bispecifics

Bio-Rad’s Pioneer Antibody Discovery Platform includes one of the largest Fab libraries ever made. The library contains over 2 x 10^11 unique human antibody sequences and has been optimized for Fab selection and IgG developability. In combination with the SpyDisplay selection technology and TrailBlazer™ modular antibody platform, Pioneer enables rapid lead candidate generation also against GPCRs. We will also introduce SpyLock, a novel approach for rapid high-throughput generation of bispecific antibodies.

May 16, 2024 / Poster

Rapid Generation of Bispecific Antibodies for High Throughput Screening with SpyLock Technology

Download the poster to:

• Learn the mechanism of SpyLock technology
• Discover the workflow for producing bispecific antibodies with SpyLock technology
• Examine data from the case study: An anti-PD-1^× anti-PD-L1 bispecific antibody

March 12, 2024 / Poster

TrailBlazer: A Rapid Modular Antibody Assembly Platform

Download this poster to learn how the TrailBlazer Platform:

• Uses SpyTag technology for the fast and simple site-specific attachment of labels to recombinant antibodies
• Enables format switching to bivalent Fabs or Ig-like antibodies within one hour
• Identifies the best format of clones for immunoassays

February 19, 2024 / Bioanalysis Zone

Rapid generation of bispecific antibodies for high-throughput screening with SpyLock technology

In this interview with John Cardone (Bio-Rad; Oxford, UK), we explore bispecifics and their impact on the biologics landscape. John explains the use of SpyLock, a new approach to bispecific screening based on SpyTag technology, for the prototyping and early screening of bispecific antibodies.

February 1, 2023 / Technology Networks

Streamlining Lead Identification

Bio-Rad recently announced the launch of their new antibody discovery service. Designed specifically for developing best-in-class biologic candidates, the Pioneer Antibody Discovery Platform is optimized to find suitable candidates for drug development.

February 3, 2023 / Technology Networks

Unlocking the Power of Therapeutic Antibodies

Join us on a journey to the forefront of therapeutic antibody development. In this podcast, you'll gain insights into how scientists and specialists at Bio-Rad are revolutionizing the biopharmaceutical industry through their customized approach to antibody discovery.

August 2, 2023 / Poster

Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform

Download the poster to:

• Learn how this new library enables rapid generation of high affinity human antibodies for therapeutic development
• Discover how Pioneer Platform delivers a greater selection of biotherapeutic candidates with diverse binding activity
• See example data for anti-TIGIT antibodies generated using the platform

October 23, 2023 / Lab Manager

Accelerating Therapeutic Antibody Development

Bio-Rad’s expansive antibody library platform sets the stage for an innovative and pioneering approach to biotherapeutic antibody discovery.

October 27, 2023 / Webinar

Versatility of Modular Antibodies: Rapid Format Switch to Fast Screening of Libraries and Bispecifics

The SpyTag/SpyCatcher protein ligation technology is a versatile method to covalently link two proteins. Addition of the SpyTag protein ligation technology to antibodies creates a modular platform that offers a wide range of new opportunities. In this webinar Dr. Ylera will demonstrate the use of Spytagged antibodies in combination with prefabricated SpyCatcher modules for rapid site-specific labeling, as well as changing antibody valency, species and isotype. Furthermore, Dr. Ylera will present the use of SpyTag for antibody phage display selection (SpyDisplay) and for the generation of prototype bispecific antibodies. The work presented illustrates how these technologies work hand in hand for the generation of new therapeutic lead candidates.

October 11, 2022 / Bioradiations

A Pioneering Approach to Biotherapeutic Antibody Discovery

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology, such as phage display, have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen.

November 14, 2022 / Press Release

Bio-Rad Introduces Pioneer Antibody Discovery Platform for Therapeutic Development

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the Pioneer Antibody Discovery Platform, a new antibody discovery service specifically designed to develop best-in-class biologic candidates.

November 21, 2022 / STAT

The Discovery of New Biologics Starts with a Diverse Library

The complete remission from advanced rectal cancer observed in all patients who participated in a small clinical trial echoed strongly in global news channels earlier in 2022 (Cercek et al., 2022). “I believe this is the first time this has happened in the history of cancer” is how the NEJM study lead, Dr L Diaz, an oncologist at Memorial Sloan Kettering Cancer Center, framed the study’s success to the New York Times.